Member Info for BuenaVista

If anyone knows, you would!

So, mulltiple people blocked? For disagreeing with his fragile ego? Ah, now I see where the circle jerk started. Please take it back to Twitter.
Me blocked? Nah, but his little poll had already closed.

This fragile ego is hilarious! Remember folks, don't disagree with RAH or you'll be binned by the control freak.

That's not the worst case. Worst case would be successive patients not completing the course.

Phase 1a will finish when it finishes. Don't worry so.

Have you not been following the rampathon Tel? Alan has already said that it works.

Thanks for the background jive. Investing in the US directly is beyond me at the moment. Perhaps when I can top slice my Avacta investment a bit, but I've got plenty of other ideas in new tech. I'll check out that read and add Caribou to the list I'm watching. Incidentally, Wassem Qasim, he of the cured child that was in the news over the weekend (and was lead item on the BBC World Service), has had patents assigned to UCL Business Ltd but has also had some co-assigned to Beam.

You mentioned two base/gene/genome editing biotech companies that you are monitoring. I don't invest in the US market but do take an interest in what's new and invest in a couple of biotech funds. Why just those two companies and not Beam (founded by Liu and Zhang) or Editas or others if there are any?

Since early last year. You obviously missed the moniker change, which I was very upfront about, although that first post has been deleted - I was temporarily banned for having two accounts until admin were informed and OK'ed the change.

Would be very worried if they hadn't claimed the patent priority back in 2020 as AS has subsequently disclosed what the invention is.

To summarise, there are three important stages to a patent application.

1st - the first filing, called the priotiry date (30/10/2020 in the US)

2nd - worldwide applications, have to be filed within one year (29/10/2021 for the WIPO filing, which covers AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)

3rd - publication, after about 6 months, so that everyone can see what has been applied for and can challenge (05/05/2022 for WIPO filing)

Then, when examined and found to be valid, and if any challenges are thrown out, the patent is granted.

Patent life is generally 20 years from the filing date of the application so, if granted, this patent will be in force, if annual fees are paid, until 29/10/2041.

Not necessarily. Such people are usually on 3 months notice.

Go back to the OP, moron.

For those reading, who don't know, a definition of Therapeutic Index is:

"The therapeutic index (TI; also known as therapeutic ratio) is a ratio that compares the blood concentration at which a drug causes a therapeutic effect to the amount that causes death (in animal studies) or toxicity (in human studies) [1]."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412688/

There are many variations but essentially it is about blood concentration for therapeutic effect vs blood concentration causing death.

The invention in the patent is about extended half-life by using a masked drug conjugate that avoids destruction (metabolism and excretion) by the liver. It is not about AVA6000. That claim for up to 10,000 times greater than the therapeutic index of the free therapeutic moiety will have come from animal studies, not from the AVA6000 trial as AVA6000 is not masked from the liver by conjugation to an Affimer binder to a serum protein.

Why 'only' 10,000? Why not 50,000 times? Probably an estimate based on the animal studies. I'm not saying this isn't good. It's bl**dy fantastic!!! But it has not come from the AVA6000 (non-TMAC) trial.

This is another view of the patent, from WIPO where the patent was published:
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022094262&_cid=P12-LBMKO1-98818-1

The priorities claimed (the same as shown in Google Patents but in a different format) are:
63/108,020 30.10.2020 US
63/197,926 07.06.2021 US

All of these predate the start of the AVA6000 trial.

I love this game of responding to the post before last...

Just chill. No news is good news. It takes as long as it takes. Wash some socks or something.

Only prob Touk is that National Lampoon’s Christening Vacation does not exist. Except in your world.

Yes, another TMAC patent. AS has already described TMAC to the original TMAC patent must have predated thast disclosure otherwise he would have invalidated any patent application.

The question is "What is new in this patent?"

- with its "priority claimed from US202063108020P",
- given that the "application claims the benefit under 35 U.S.C. § 119(e) of US 63/108,020, filed October 30, 2020 and US 63/197,926, filed June 7, 2021, which are incorporated by reference herein in their entireties."

That's a rhetorical question. Well, it's for the poor sods in the patent offices to determine.

It may well be the 'extended half-life' but no one here is going to say for sure.

Is that what's already in the pipeline?

https://avacta.com/therapeutics/pipeline/

You're congenitally stupid.

Unless I've misunderstood TMAC, which I probably have!

For TMAC, see claims 5 and 7/8/9.

Wow! Great find ES.

It seems to be a way of extending the circulating half-life of the pre|CISION prodrugs by linking 5140 to a serum protein OR... and this is where it gets very interesting... to a moiety that binds to a serum protein. All possibilities for that moiety are given of course (covering all bases) but amongst them are Affimers®. That would be TMAC™.

So the 'drug' is cytotoxic agent linked to 5140 linked to Affimer which binds to a serum protein which carries the drug around the body, avoiding the destruction in the liver because the liver lets serum proteins through unharmed - imagine the problems to you, me and all aninals with a liver if it didn't!

The only thing I don't understand is how, physically, the dipeptide linker (5140) is connected to both the cytotoxic agent and the Affimer when the dipeptide linker is the 'key' that fits into the FAP 'lock' in order for the FAP enzyme to cleave the prodrug off. Logic says that the Affirmer (big enough to bind to the serum protein) would need to be inside the lock space as well as the dipeptide. Probably explained within the many diagrams of chemical structures shown in the patent but not something I need to devote time to - what will be will be.

I'd just like to say that my total admiration goes to those folks who direct the research in order to define the extend and boundaries of the invention, who construct the patent specification, who write the patent application and who translate it into other languages, as well as the poor sods at the various patent offices who have to examine it for novelty.